Life Sciences

Digital phenotyping
and
biomarker
capabilities

Huma’s digital phenotyping and biomarker capabilities can provide more comprehensive, objective, and continuous pictures of human function in health and disease. This data is advancing predictive health and personalised medicine and is improving the efficiency of clinical trials.

The current situation

The unmet need
in research
and
clinical care

In research and clinical care, a participant or patient’s disease progression is observed through episodic clinical visits, meaning fluctuations in disease progression are not always captured. Assessments are also often observational rather than quantitative, resulting in a subjective analysis of the disease state or treatment outcome.

There is an urgent need for more objective, sensitive, and continuous descriptions of disease signs and how patients feel and function.

Huma can improve
research
and
clinical care

Huma’s portfolio of digital phenotyping capabilities and digital biomarkers bring precision and holistic insights into drug development and clinical practice, and can enable personalised approaches to treatment.

The opportunity in
data collection

Patients spend the majority of their time outside of a clinical setting. Traditional clinical visits limit observations to episodic assessments, potentially missing critical insights into disease signs and progression 1.

Illustration of man in armchair with phone.
Our solution

Smartphones and wearables can continuously collect health information and provide a more comprehensive picture of disease burden and progression, that would otherwise be hidden in standard clinical visits.

The opportunity in measurement

Many assessments performed in the clinical setting, such as self-reported information and rating scales, are subjective, rather than objective 2.

Illustration of man looking at mobile.
Our solution

Digital biomarkers provide unbiased, objective assessments of clinical status and therapeutic effects, and can enable a predictive and personalised approach to treatment and care.

The opportunity in assessment

Traditional clinical biomarkers can be invasive and expensive to measure, requiring trained personnel in clinical practice 3.

Illustration of woman on laptop, heart and thermometer icons.
Our solution

Digital biomarkers provide unbiased, objective assessments of clinical status and therapeutic effects, and can enable a predictive and personalised approach to treatment and care.

  • Data Collection
  • in measurement
  • in assessment

Huma’s portfolio of
digital biomarkers

Huma is developing a portfolio of digital biomarkers and digital measures across a number of disease areas, both independently and in partnership with other life science companies.

These measures are being used by our life science and healthcare partners to advance diagnosis, prognosis, tailor treatment decisions, and improve the assessment of therapeutics outcomes in both clinical trials and practice.

cardiology
Cardiology
oncology
Oncology
diabetes
Diabetes & Endocrinology
neurology
Neurology
covid-19
COVID-19

Huma's digital
phenotyping
capabilities

Huma has developed a portfolio of digital tools and capabilities that utilise the sensors and data collection capabilities of personal smartphones, wearables, and other connected devices. We are deploying these tools through our digital platforms to help our partners build-up a comprehensive, real-life digital picture (or digital phenotype), and how an individual is feeling and functioning.

Cognition
Mental health
Fine Motor
Anthropometrics
Sleep/Circadian Rythm
Illustration of man looking at mobile.
Oxygen sats and RR
Gross Motor
Speech
Wearables & sensors
Heart rate & HRV
  • Digital Biomarkers
  • digital phenotyping

Our offering

How digital biomarkers
can help you

participants and carers
Participants/Carer

Less invasive assessments, provided outside of a clinical setting, reducing the burden on participants/carers.

Improved patient monitoring, enabling more holistic, precise measurements of disease signs and/or treatment outcome.

More accessible and patient-centric.

pharma
Pharma

Objective, precise, and unbiased clinical trial endpoints, that potentially increase the opportunity for success, and reduce study timelines and size.

More holistic pictures of disease signs and symptoms, that uncover novel insights, enabling the development of more personalised treatments.

Less invasive assessments, that reduce the burden on participants to engage in trials, improving recruitment and retention.

Participants/Carer

Less invasive assessments, provided outside of a clinical setting, reducing the burden on participants/carers.

Improved patient monitoring, enabling more holistic, precise measurements of disease signs and/or treatment outcome.

More accessible and patient-centric.

Pharma

Objective, precise, and unbiased clinical trial endpoints, that potentially increase the opportunity for success, and reduce study timelines and size.

More holistic pictures of disease signs and symptoms, that uncover novel insights, enabling the development of more personalised treatments.

Less invasive assessments, that reduce the burden on participants to engage in trials, improving recruitment and retention.

  • Participants/Carer
  • Pharma

Why Huma?

Benefits of
collaborating with
Huma
on digital
biomarkers

machine learning
Machine learning and
AI expertise

Extensive in-house data science team
with a deep understanding of and
expertise in extracting novel insights
from high dimensional datasets.

engagement
Engaging user
experience for patients

Deep understanding of the importance of
user experience research and design to
ensure users can reliably operate digital
biomarker modules and deliver solutions
that easily fit into their daily lives.

regulators
Regulatory landscape
knowledge

Strong understanding of the evolving
regulatory landscape for digital
biomarkers and measures

globally deployable
Global network of
academic medical centers

Wide network of leading researchers,
clinical experts and research-grade
patient data to efficiently refine and
validate digital measures.

trusted partners
Trusted Partner

Our digital measures are all built
under a Quality Management System
compliant with global security, privacy
and regulatory requirements.

experienced
Experienced

Partnerships with top 10 pharma
companies and leading academic
research institutions to develop novel
digital measures.

device agnostic
Device Agnostic

Digital biomarker solutions available
on both iOS and Android, and
integrate and gather data from 400+
wearables devices.

Machine learning and AI expertise

Extensive in-house data science team with a deep understanding of and expertise in extracting novel insights from high dimensional datasets.

Engaging user experience for patients

Deep understanding of the importance of user experience research and design to ensure users can reliably operate digital biomarker modules and deliver solutions that easily fit into their daily lives.

Regulatory landscape knowledge

Strong understanding of the evolving regulatory landscape for digital biomarkers and measures.

Global network of academic medical centers

Wide network of leading researchers, clinical experts and research-grade patient data to efficiently refine and validate digital measures.

Trusted Partner

Our digital measures are all built under a Quality Management System compliant with global security, privacy and regulatory requirements.

Experienced

Partnerships with top 10 pharma companies and leading academic research institutions to develop novel digital measures.

Device Agnostic

Digital biomarker solutions available on both iOS and Android, and can integrate and gather data from 400+ wearables devices.

  • Machine learning
  • user experience
  • Regulatory knowledge
  • Global network
  • Trusted Partner
  • Experienced
  • Device Agnostic
case studies
mobile

Case Studies

ReVeRe® -
Early detection of
Alzheimer’s disease

In partnership with Johnson & Johnson, Huma are further validating and commercialising a digital biomarker focussed on early detection and monitoring of Alzheimer’s disease, through assessing verbal learning via voice recognition technology.

Listen, Recall, Start speaking, Alzheimer's detection app on mobile.
Listen, Recall, Start speaking, Alzheimer's detection app on mobile.

Case Studies

COVID-19 Severity
Risk Score

Huma have partnered with Johns Hopkins to develop a COVID-19 severity risk score that assesses an individual’s risk of developing severe complications.

The COVID-19 Risk Score is based on a meta-analysis of 1,800 medical papers and combines 31 criteria and risk factors associated with COVID-19.

case study 3
case study 3

Case Studies

Digital measure of
mobility and frailty

As part of a companion app to support patients with pulmonary arterial hypertension, Huma together with Bayer, are further validating a digital version of the clinical Timed Up and Go test, which measures a person’s mobility.

case study 4
case study 4

Case Studies

Breathing rate

Huma is developing a technology that allows a patient to capture their breathing rate utilising the motion sensors of the smartphone. Tracking changes in breathing gives patients and their clinicians a chance to spot early warning signs of deterioration in a range of conditions, including COVID-19.

case study 5
case study 5

Case Studies

Detection of motor
deterioration in
Parkinson's disease

Huma and Tencent Medical AI Lab partnered to evaluate a novel motion capture and Tencent's AI technology to assess motor functions of people with Parkinson's disease in the real-world setting, using smartphones.

The study aims to advance the early diagnosis of Parkinson's disease, screening, and daily monitoring of disease progression.

  • 01
  • 02
  • 03
  • 04
  • 05

This field is required

This field is required

This field is required

This field is required

This field is required

Huma is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

By clicking submit below, you consent to allow Huma to store and process the personal information submitted above to provide you the content requested.

thumbs up
One of our team members will be in touch with you shortly.
There was an error submitting your form. Please refresh and try again.

Sources
1.

Understanding Commonly Encountered Limitations in Clinical Research: An Emergency Medicine Resident’s Perspective. Jones, Christopher W. and Platts-Mills, Timothy F. MD (2011) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539753/

2.

Traditional and Digital Biomarkers: Two Worlds Apart.Babrak, L.M. and Menetski, J. (2019)